Founder & CEO of JoinCare. Academician and global innovation strategist. Focused on life-science translation, intelligent industry and future research systems.
Global / Berlin / Oxford
Joined June 2026
- Tweets41
- Following26
- Followers221
- Likes33
AI, biology and advanced manufacturing will reshape healthcare.
The winners will be those that integrate them into operating models, not slogans.
Peter Sachsenmeier retweeted
200,000 check-ins. All on-chain.
Let’s keep that counter moving.
Check in today: joincarelabs.com/tasks
In health, reputation is balance-sheet value.
Trust, quality and compliance are not soft assets. They shape how far a biomedical company can go.
The boardroom question is simple:
Where can we build biomedical capabilities that will still matter ten years from now?
Short-term opportunities come and go. Durable scientific capability compounds.
Healthcare is becoming a systems business.
Products still matter, but the lasting advantage will come from platforms, ecosystems and the ability to connect science, data, regulation and execution.
Investors should look beyond pipelines.
I would pay just as much attention to whether a company can translate good science at scale.
The biomedical sector is entering a consolidation phase. Scale, focus and trusted execution will matter more than hype.
JoinCare must think like a health platform company: science-led, quality-driven and globally connected.
In biomedicine, execution is strategy. A brilliant discovery has limited value unless it can be produced, approved and trusted.
Peter Sachsenmeier retweeted
A promising biomedical project should be able to answer three questions:
What problem is it solving?
What evidence supports the idea?
What experiment comes next?
Early-stage science is uncertain. It should not be unclear.
That is the standard behind JoinCare.
I have become careful with big technology promises.
Every new wave brings real potential.
It also brings a lot of noise.
So I try not to ask what is fashionable.
I ask what problem is actually being solved.
This is why I decided to build JoinCare.
Not as another platform chasing attention.
But as a way to help researchers, medical experts, contributors, and communities organize around evidence, risk, and long-term value.
Peter Sachsenmeier retweeted
🤝 JoinCare × Roam
We’re excited to partner with Roam @weRoamxyz , a DePIN wireless platform using OpenRoaming and eSIM to deliver secure, seamless global connectivity.
Together, we’ll explore DeSci outreach, joint community initiatives, and future platform integrations.
It was a pleasure to exchange views with Dr. Masanori Isogawa and the team at NIID.
Scientific progress begins with open dialogue, mutual respect, and a willingness to learn from one another.
European news outlet Brussels Standard covered JoinCare’s recent visit to Japan’s NIID.
Our CEO Peter Sachsenmeier @PeterJoinCare met Dr. Masanori Isogawa to discuss virology, infectious disease prevention, and early-stage biomedical innovation.
Read the full story 👇brusselsstandard.eu/2026/07/…
People like beginnings and endings.
The breakthrough.
The announcement.
The success story.
But most serious innovation happens in the middle.
Many good ideas disappear here.
Not because the science had no value.
Because the system around it was not strong enough to carry it forward.